Alcon, a global leader in eye care, has acquired BELKIN Vision for a total upfront consideration of $81 million. The deal also includes the potential for up to $385 million in payments based on sales-based milestones. The acquisition includes BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology, expanding Alcon’s glaucoma portfolio with a first-line therapy. For glaucoma, Alcon also offers implantables such as Hydrus Microstent, and pharmaceutical drops that are currently ava...